Anti-IL-6R therapy on Graves' ophthalmopathy

Butnaru, Dana; Pérez-Moreiras, J.V.; Sánchez-Ramón, Silvia

doi:10.1016/j.clim.2013.02.017

Cited by 10 publications

(8 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Orbital fibroblasts produce excessive IL-6, which recruits and activates T cells to induce the synthesis of hydrophilic glycosaminoglycans, with effects on other immune cells. The improvement of several adult cases of severe thyroid eye disease following tocilizumab therapy has been reported [81, 82]. Moreover, a randomized clinical trial demonstrated the meaningful efficacy of tocilizumab in 32 patients with moderate to severe corticosteroid-resistant Graves’ orbitopathy [83].…”

Section: Resultsmentioning

confidence: 99%

Off-label use of tocilizumab to treat non-juvenile idiopathic arthritis in pediatric rheumatic patients: a literature review

et al. 2018

View full text Add to dashboard Cite

Tocilizumab, an anti-interleukin-6 (IL-6) agent, is indicated as a treatment for several autoimmune or inflammatory diseases, including rheumatoid arthritis and juvenile idiopathic arthritis (JIA). IL-6 plays roles in both immune system dysregulation and inflammation, and thus efforts to extend the utility of tocilizumab in patients with autoinflammatory conditions are ongoing. Here, we survey the literature on the off-label use of tocilizumab in patients with juvenile-onset rheumatic diseases including juvenile systemic lupus erythematosus (SLE), juvenile dermatomyositis (DM), vasculitis, juvenile scleroderma, and other autoinflammatory diseases. There is no real evidence that tocilizumab is useful for patients with SLE and juvenile DM, but several cases of childhood Takayasu arteritis have experienced promising outcomes. In juvenile-onset scleroderma, for which no therapy that can halt disease progression is available, tocilizumab may stop progression and the associated functional impairment. Tocilizumab prevents systemic inflammation in patients with Kawasaki’s disease, but may develop coronary aneurysms. Tocilizumab has been used to treat several pediatric autoinflammatory diseases, including JIA-associated uveitis and Castleman’s disease. Further work in larger populations is necessary to confirm the effects of tocilizumab in patients with pediatric rheumatic diseases.

show abstract

Section: Resultsmentioning

confidence: 99%

Off-label use of tocilizumab to treat non-juvenile idiopathic arthritis in pediatric rheumatic patients: a literature review

et al. 2018

View full text Add to dashboard Cite

show abstract

“…etanercept, showed more beneficial effects than did placebo [91]. Successful treatment of a single patient with anti-interleukin-6 receptor monoclonal antibody (tocilizumab) was recently reported [92]. A novel somatostatin analog, i.e.…”

Section: Perspectivesmentioning

confidence: 99%

Graves' Orbitopathy: Imperfect Treatments for a Rare Disease

Bartalena

2013

Eur Thyroid J

View full text Add to dashboard Cite

Graves' orbitopathy (GO) is the most frequent and invalidating extrathyroidal expression of Graves' disease. Its incidence and prevalence are, however, low. About three quarters of Graves' patients have no GO at diagnosis, and moderate-to-severe and severe forms represent no more that 5-6% of cases. Progression to severe forms occurs rarely, but it may be caused by risk factors, the most important being smoking and poor control of thyroid dysfunction. Lot of progress has been recently achieved in the understanding of GO pathogenesis, while the disease remains a therapeutic challenge and dilemma. Common treatments for moderate-to-severe and active forms of GO (glucocorticoids and orbital radiotherapy) frequently provide incomplete responses and may be followed by relapse or progression of GO. After the disease has been inactivated by medical treatment, many patients need rehabilitative surgery for residual manifestations (orbital decompression for exophthalmos, squint surgery for extraocular muscle dysfunction, eyelid surgery for eyelid malposition). Novel pharmacological treatments are on the horizon and might target pathogenetic mechanisms of the disease better than glucocorticoids. Clinical evidence concerning their efficacy and safety is presently lacking.

show abstract

“…Of the 24 articles on this Mab, 62.5% originated from European countries. 34,39,41,49,58,59,63,68,69,71,72,79,80,84 The same trend is true for Rituximab (64.3% articles from Europe). 26,27,30,33,35,37,42–44,46–48,54,55,61,62,65,67,73,89 In contrast, Teprotumab has only been tested in the USA.…”

Section: Resultsmentioning

confidence: 61%

“…1 shows that 76 articles of the 954 screened records were included in the review. The literature on the use of Mabs for treating GO has been centered on blockage of IL-6 (Tocilizumab), 34,39,41,49,50,53,56,[58][59][60]63,64,[68][69][70][71][72]79,80,84,87,90,[96][97][98] anti-CD20 lymphocytes (Rituximab), [26][27][28][29][30][31][32][33]35,37,38,40,[42][43][44][45][46][47][48]51,54,55,61,62,65,…”

Section: Resultsmentioning

confidence: 99%

Monoclonal Antibodies for the Treatment of Graves Orbitopathy: Precision Medicine?

Xavier

Lucena

Cruz

2023

Ophthalmic Plastic &Amp; Reconstructive Surgery

View full text Add to dashboard Cite

Purpose: To summarize the development, nomenclature, and rationale of the reported use of monoclonal antibodies (Mabs) in Graves Orbitopathy (GO) and to undertake a systematic review of the management of GO with Mabs. Methods: The Pubmed and Embase databases and the Federal Brazilian searching site (Periódicos-CAPES) were screened. The authors searched all the keywords “monoclonal antibodies,” “adalimumab,” “belimumab,” “infliximab,” “rituximab,” “teprotumumab,” and “tocilizumab” combined with the terms “Graves Orbitopathy,” “Graves eye disease” and “thyroid eye disease.” All the articles published in English, French, and Spanish from 2000 to May 2022 were screened. Only publications with quantitative data on the activity of orbitopathy, proptosis, or both were included. Results: Seventy-six articles of the 954 screened records met the inclusion criteria. Seven Mabs were described for treating GO. The three most reported Mabs were Rituximab, Tocilizumab, and Teprotumumab. Only eight randomized clinical trials compared the effect of these three Mabs and Belimumab with the effect of steroids or placebos. Adalimumab, Infliximab, and K1-70 only appeared in a few case series and case reports. Frequent mild-to-moderate and few major side effects occurred with the three most used Mabs. Relapse rates ranged from 7.4% for Tocilizumab to at least 29.4% for Teprotumumab. No randomized clinical trials compared Mabs head-to-head. Conclusion: Considering the lack of head-to-head comparisons between Mabs, the relapse rate, the possibility of severe collateral effects, and the cost of Mabs, it is not clear which Mab is the safest and most useful to treat GO.

show abstract

Anti-IL-6R therapy on Graves' ophthalmopathy

Cited by 10 publications

References 6 publications

Off-label use of tocilizumab to treat non-juvenile idiopathic arthritis in pediatric rheumatic patients: a literature review

Off-label use of tocilizumab to treat non-juvenile idiopathic arthritis in pediatric rheumatic patients: a literature review

Graves' Orbitopathy: Imperfect Treatments for a Rare Disease

Monoclonal Antibodies for the Treatment of Graves Orbitopathy: Precision Medicine?

Contact Info

Product

Resources

About